# MicroRNA Expression Profile in Endometriosis and Endometriosis-Associated Ovarian Cancer—Systematic Review

**Authors:** Maria Szubert, Iwona Gabriel, Aleksander Rycerz, Monika Golińska, Jacek R. Wilczyński

PMC · DOI: 10.3390/cells15040374 · Cells · 2026-02-20

## TL;DR

This review finds inconsistent miRNA patterns in endometriosis and related ovarian cancer, suggesting the need for better sequencing methods.

## Contribution

Highlights the lack of consistent miRNA profiles and proposes NGS as a solution for improving study comparability.

## Key findings

- No consistent miRNA up- or downregulation was observed across all studies.
- High heterogeneity of samples prevents meta-analysis of miRNA data.
- NGS could improve accuracy by overcoming reference gene limitations.

## Abstract

What are the main findings?
Out of 2387 screened manuscripts, 13 studies originated from diverse geographic regions and included both patients with endometriosis and ovarian cancer diagnosed simultaneously or consecutivelyNo consistent miRNA up- or downregulation was observed across all studies

Out of 2387 screened manuscripts, 13 studies originated from diverse geographic regions and included both patients with endometriosis and ovarian cancer diagnosed simultaneously or consecutively

No consistent miRNA up- or downregulation was observed across all studies

What are the implications of the main findings?
Current results in the literature related to miRNA do not allow conclusions to be drawn on the disrupted pattern leading from endometriosis to endometriosis-associated ovarian cancerThe use of Next-Generation Sequencing (NGS) could help overcome limitations related to the selection of different reference genes in miRNA studies and improve the accuracy of relative expression analyses.

Current results in the literature related to miRNA do not allow conclusions to be drawn on the disrupted pattern leading from endometriosis to endometriosis-associated ovarian cancer

The use of Next-Generation Sequencing (NGS) could help overcome limitations related to the selection of different reference genes in miRNA studies and improve the accuracy of relative expression analyses.

Endometriosis-associated ovarian cancer comprises a special group of ovarian cancers that most probably originate from endometriosis foci. Several in vitro studies have shown that microRNA (miRNA) plays an important role in this carcinogenesis. Our goal was to establish if a distinct miRNA profile can be associated with endometriosis and endometriosis-associated ovarian cancer with their potential causal relationship, and whether such a profile could be used clinically to prognose carcinogenesis in endometriosis foci. We conducted a systematic search according to PRISMA guidelines, registered at PROSPERO (number CRD42021245606). The search encompassed whole Pubmed, Cochrane and Medline databases to 1 May 2025 and the search strategy included the following [MeSH] terms: ‘miRNAs’ or ‘microRNAs’ or ‘miR’ and ‘ovarian cancer’ and ‘endometriosis’. Our ultimate inclusion criterion was that studies must simultaneously evaluate miRNA expression in endometriosis, regardless of its form and stage, and in endometriosis-associated ovarian cancer (EAOC), as only data generated under identical experimental conditions and using the same controls are truly comparable. The quality of the data was assessed using The Newcastle-Ottawa scale (NOS) and ROBINS-I tool. Our final analysis included 13 studies, comprising 608 patients and over 1000 miRNA molecules. Among those only five manuscripts presented raw data for each miRNA studied. Although several authors declared high sensitivity and specificity for one or more miRNA in distinguishing between endometriosis and endometriosis-associated ovarian cancer, a meta-analysis could not be performed due to the high heterogeneity of the studied samples. We concluded that there is not enough publicly available raw data to establish a set of miRNAs capable of differentiating between the two diseases and of prognosing carcinogenesis. The greatest limitation lies in the use of various standardized reference gene sets, which makes it impossible to compare relative miRNA expression across studies. New data from the next generation sequencing (NGS) experiments would overcome issues related to reference and control genes.

## Linked entities

- **Diseases:** endometriosis (MONDO:0005133), ovarian cancer (MONDO:0005140)

## Full-text entities

- **Genes:** PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, MIR191 (microRNA 191) [NCBI Gene 406966] {aka MIRN191, miR-191}, MIR145 (microRNA 145) [NCBI Gene 406937] {aka MIRN145, miR-145, miRNA145}, ARID1A (AT-rich interaction domain 1A) [NCBI Gene 8289] {aka B120, BAF250, BAF250a, BM029, C1orf4, CSS2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, PDCD4 (programmed cell death 4) [NCBI Gene 27250] {aka H731}, MIR99B (microRNA 99b) [NCBI Gene 407056] {aka MIRN99B, mir-99b}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, MIR143 (microRNA 143) [NCBI Gene 406935] {aka MIRN143, mir-143}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, GDE1 (glycerophosphodiester phosphodiesterase 1) [NCBI Gene 51573] {aka 363E6.2, MIR16}, MIR125A (microRNA 125a) [NCBI Gene 406910] {aka MIRN125A, miRNA125A, mir-125a}, TIMP3 (TIMP metallopeptidase inhibitor 3) [NCBI Gene 7078] {aka HSMRK222, K222, K222TA2, SFD}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, MIR20A (microRNA 20a) [NCBI Gene 406982] {aka C13orf25, MIR20, MIRH1, MIRHG1, MIRN20, MIRN20A}
- **Diseases:** renal cancer (MESH:D007680), hypoxia (MESH:D000860), endometrial ovarian cyst (MESH:C536396), endometriotic lesions (MESH:D009059), clear cell cancer (MESH:D018295), epithelial ovarian cancer (MESH:D000077216), carcinogenesis (MESH:D063646), ischemic (MESH:D002545), endometrioid carcinoma (MESH:D018269), cancer (MESH:D009369), serous (MESH:D018297), melanoma (MESH:D008545), injury to (MESH:D014947), inflammation (MESH:D007249), Endometriosis (MESH:D004715), ovarian (MESH:D010049), brain tumor (MESH:D001932), breast cancer (MESH:D001943), associated (MESH:D018886), Endometriosis-associated ovarian cancer (MESH:D010051), positive (MESH:D000377), carcinogenic transformation (MESH:D002472), metastasis (MESH:D009362), thyroid cancer (MESH:D013964)
- **Chemicals:** paraffin (MESH:D010232), formalin (MESH:D005557)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12939174/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939174/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC12939174/full.md

---
Source: https://tomesphere.com/paper/PMC12939174